BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 23291138)

  • 1. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
    Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 3. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer.
    Lee DJ; Sohn TS; Lim DH; Ahn HK; Park SH; Lee J; Park JO; Park YS; Lim HY; Choi DI; Kim KM; Choi MG; Noh JH; Bae JM; Kim S; Min BH; Kang WK
    Cancer Chemother Pharmacol; 2012 May; 69(5):1333-8. PubMed ID: 22311161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
    Park I; Lee JL; Ryu MH; Chang HM; Kim TW; Sym SJ; Lee SS; Jang G; Yoo C; Bae KS; Kang YK
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):473-80. PubMed ID: 19551382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
    BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.
    Zhong DT; Wu RP; Wang XL; Huang XB; Lin MX; Lan YQ; Chen Q
    Pathol Oncol Res; 2015 Sep; 21(4):867-73. PubMed ID: 25648439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma.
    Honma Y; Yamada Y; Terazawa T; Takashima A; Iwasa S; Kato K; Hamaguchi T; Shimada Y; Ohashi M; Morita S; Fukagawa T; Machida N; Katai H
    Surg Today; 2016 Sep; 46(9):1076-82. PubMed ID: 26563224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
    Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
    Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
    Feng D; Leong M; Li T; Chen L; Li T
    World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
    Li J; Lu M; Shen L; Zhang XD; Li Y
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):933-6. PubMed ID: 20193337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
    Yamada Y; Koizumi W; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Hyodo I
    Cancer Sci; 2019 Sep; 110(9):2875-2883. PubMed ID: 31254422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Experience of S-1 and Oxaliplatin(SOX)as the First-Line Chemotherapy for Metastatic/Recurrent Gastric Cancer].
    Toyokawa T; Tamura T; Shibutani M; Ohira G; Yamazoe S; Kimura K; Nagahara H; Amano R; Tanaka H; Muguruma K; Yashiro M; Hirakawa K; Ohira M
    Gan To Kagaku Ryoho; 2017 May; 44(5):405-408. PubMed ID: 28536336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Jeong SH; Joo YT; Lee YJ; Cho Sh; Kang MH; Go SI; Lee GW; Kim Hg; Kang JH
    Invest New Drugs; 2012 Feb; 30(1):350-6. PubMed ID: 20706861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination Chemotherapy Using Oxaliplatin plus S-1 for Well-Advanced Gastric Cancer].
    Saito H; Suematsu Y; Yamagishi S; Takahashi M; Nakayama M; Fukabori M; Morita A; Wakabayashi K; Itoh Y
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1933-1935. PubMed ID: 28133180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.